Christopher L. Wight
Salt Lake City
Christopher Wight’s practice focuses on providing intellectual property legal services and strategic counseling for the life science and chemical industries, specifically in the chemical, pharmaceutical, biotechnology, medical diagnostic/personalized medicine and medical device fields.
Mr. Wight has previously been affiliated with several nationally and internationally recognized law firms specializing in intellectual property matters. Mr. Wight has also served as in-house counsel to two highly successful biopharmaceutical and molecular diagnostic companies – as Vice President and General Counsel of Myriad Genetics and as Director of Intellectual Property of Immunex Corporation prior to its acquisition by Amgen. At Immunex, Mr. Wight was personally responsible for developing and implementing Immunex’s corporate intellectual property strategy for various biopharmaceutical products, including LEUKINE and ENBREL. ENBREL is now one of the world’s highest grossing biologic drugs, with current world-wide annual revenues exceeding $8 billion. Immunex’s ENBREL product and the strength of its patent portfolio developed by Mr. Wight was the principal economic driving force behind Amgen’s $16 billion acquisition of Immunex in 2002, then the largest acquisition of a biopharmaceutical company in the history of the biotechnology industry.
As Vice President & General Counsel of Myriad Genetics, Mr. Wight was responsible for directing the development and enforcement of intellectual property relating to Myriad’s genetic testing business, including Myriad’s patents covering its BRACANALYSIS breast cancer predisposition test, which positioned Myriad to become the preeminent genetic testing company in the world.
Mr. Wight has also previously represented numerous major pharmaceutical companies around the world, including one of the world’s largest generic drug manufacturers, providing patent invalidity analyses and opinions relating to branded innovator drugs in support of Hatch-Waxman Act Paragraph IV Certifications.